Study for Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Inclusion Criteria:
*  Have been diagnosed with type 2 diabetes mellitus (T2DM)
*  Are at least 18 years of age or legal age of consent in the jurisdiction in which the study is taking place, whichever is older.
*  Have HbA1c at screening
*  ≥7.0% and ≤10.5% if background diabetes medication does not include a sulfonylurea, or
*  ≥7.5% and ≤10.5% if background diabetes medication includes a sulfonylurea.
*  Are on stable treatment of at least 1 and no more than 3 oral antihyperglycemic drugs for at least 90 days before screening. Antihyperglycemic drugs may include metformin, SGLT-2 inhibitors, and/or sulfonylureas
*  Have increased risk for cardiovascular (CV) events due to:
*  Coronary heart disease
*  Peripheral arterial disease, presumed to be of atherosclerotic origin
*  Cerebrovascular disease, presumed to be of atherosclerotic origin
*  Chronic kidney disease (CKD)
*  Congestive heart failure (CHF) New York Heart Association (NYHA) functional classification II to III
*  Are of stable weight (± 5%) for at least 90 days prior to screening
*  Have a BMI ≥25 kilograms per meter squared (kg/m2) at screening

Exclusion Criteria:
*  Have type 1 diabetes mellitus
*  Have had chronic or acute pancreatitis any time prior to screening
*  Currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema (e.g. laster photocoagulation or intravitreal injections of anty-VEGF inhibitors
*  Have a known clinically significant gastric emptying abnormality
*  Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or blood alanine transaminase (ALT) or aspartate aminotransferase (AST) enzyme level ≥5.0 times the upper limit of normal (ULN) for the reference range, as determined by the central laboratory
*  Have had any of the following within 60 days prior to screening: acute myocardial infarction, cerebrovascular accident (stroke), or hospitalization for congestive heart failure
*  Have an eGFR \<15 mL/min/1.73 m2 as determined at screening
*  Have a family (first-degree relative) or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
*  Have been taking any other diabetes medicines other than metformin, SGLT-2 inhibitors, and/or sulfonylureas during the last 90 days
*  Have used any weight loss drugs, including herbal or nutritional supplements, within 90 days of screening